Benefits of using cannabidiol in the treatment of motor and non-motor symptoms of Parkinson's disease: A systematic review

Authors

DOI:

https://doi.org/10.33448/rsd-v14i2.48325

Keywords:

Parkinson’s; Cannabidiol; Neurodegeneration.

Abstract

Parkinson's Disease (PD) is a chronic neurodegenerative condition, common in people over 65 years of age, characterized by the loss of dopaminergic neurons in the substantia nigra, which results in a decrease in dopamine in the brain. Conventional treatments, such as dopamine administration, have limited effectiveness over time, which can cause tardive dyskinesia. Seeking new therapeutic options, cannabinoids, such as cannabidiol (CBD), have been investigated due to their potential to modulate several biological pathways, including the reduction of motor and non-motor symptoms, in addition to combating inflammation and oxidative stress. This study aimed to carry out a Systematic Literature Review, which evaluated the effects of CBD on the motor and non-motor symptoms of PD, following the PRISMA protocol. Articles were searched in English, Portuguese and Spanish in the PubMed and Lilacs databases until 2023. The studies revealed varied results: some indicated benefits in pain control and quality of life, but also pointed out adverse effects such as drowsiness and dizziness. The effectiveness of CBD in improving motor symptoms has been inconsistent, and the combination with THC has had a negative impact on cognition in some patients. Studies suggest that CBD may be useful in treating the non-motor symptoms of PD, but more rigorous research with larger samples is needed to confirm its long-term impact and determine which patients would benefit most from this therapy.

References

Bahji, A., et al. (2022). Cannabinoids in the management of symptoms of neurocognitive disorders: A mixed studies review. Journal of Cannabis Research, 4(1), 11. https://doi.org/10.1186/s42238-022-00119-y

Braak, H., & Del Tredici, K. (2008). Nervous system pathology in sporadic Parkinson disease. Neurology, 70(20), 1916-1925. https://doi.org/10.1212/01.wnl.0000312279.49272.9f

Camargo Filho, M. F. A., et al. (2019). Canabinoides como nova opção terapêutica nas doenças de Parkinson e Alzheimer. Revista Brasileira de Neurologia, 55(2), 17-32.

Di Luca, D. G., et al. (2023). A Phase Ib, randomized study of cannabis oil for pain in Parkinson's disease. Movement Disorders Clinical Practice, 10(7), 1114-1119. https://doi.org/10.1002/mdc3.13754

Domen, C. H., et al. (2023). Cognitive safety data from a randomized, double-blind study on the effects of cannabidiol and THC on Parkinson's disease. Movement Disorders, 38(7), 1341-1346. https://doi.org/10.1002/mds.29447

Esposito, G., et al. (2006). Cannabidiol inhibits tau hyperphosphorylation through Wnt/beta-catenin pathway in PC12 cells. Journal of Molecular Medicine (Berl.), 84(3), 253-258. https://doi.org/10.1007/s00109-005-0025-1

Faria, S. M., et al. (2020). Effects of acute cannabidiol on anxiety and tremors in Parkinson's disease. Journal of Psychopharmacology, 34(2), 189-196. https://doi.org/10.1177/0269881119895536

Lastres-Becker, I., & Fernández-Ruiz, J. (2006). Overview of Parkinson's disease and the cannabinoid system. Current Medicinal Chemistry, 13(30), 3705-3718. https://doi.org/10.2174/092986706779026156

Junior, N. C. F., et al. (2020). Cannabidiol as potential strategy for treating Parkinson's disease and L-DOPA-induced dyskinesia. Neurotoxicology Research, 37(1), 12-29. https://doi.org/10.1007/s12640-019-00109-8

Matos, R. L. A., et al. (2017). O uso do canabidiol no tratamento da epilepsia. Revista Virtual Química, 9(2), 786-814. https://doi.org/10.33448/rsd-v11i16.38057

Oikonomou, P., & Joost, W. H. (2022). Randomized trials on cannabis-based medicines in movement disorders: A systematic review. Journal of Neural Transmission (Vienna), 129(10), 1247-1256. https://doi.org/10.1007/s00702-022-02529-x

Pereira A. S. et al. (2018). Metodologia da pesquisa científica. [free e-book]. Editora UAB/NTE/UFSM. 8.2)

Peternella, F. M. N., & Macon, S. S. (2009). Descobrindo a Doença de Parkinson: Impacto para o Parkinsoniano e seu familiar. Revista Brasileira de Enfermagem, 62(1), 1-2.

Pisanti, S., et al. (2017). Cannabidiol: State of the art and new challenges for therapeutic applications. Pharmacology & Therapeutics, 175, 133-150. https://doi.org/10.1016/j.pharmthera.2017.02.041

Poças, C. S. (2017). Canabinóides – Perspetivas no tratamento da Doença de Parkinson [Dissertação de doutorado, Universidade de Coimbra]. http://hdl.handle.net/10316/83792

Rieder, C. R. (2020). Cannabidiol in Parkinson’s disease. Brazilian Journal of Psychiatry, 42(2), 126–127. https://doi.org/10.1590/1516-4446-2019-0810

Shitsuka, R. et al. (2014). Matemática fundamental para tecnologia. 2ed. Editora Erica

Stampanoni Bassi, M., et al. (2017). Cannabinoids in Parkinson's disease. Cannabis and Cannabinoid Research, 2(1), 21-29. https://doi.org/10.1089/can.2017.0002

Souza, E. L., et al. (2021). A doença de Parkinson pela COVID-19: Fisiopatologia do canabidiol. Brazilian Journal of Health Review, 4(5), 19496-19504. https://doi.org/10.34119/bjhrv4n5-083

Thanabalasingam, S. J., et al. (2021). Cannabis for motor symptoms in Parkinson's disease: A systematic review and meta-analysis. Therapeutic Advances in Neurological Disorders, 14, 17562864211018561. https://doi.org/10.1177/17562864211018561

Downloads

Published

25/02/2025

How to Cite

BORGES, P. G. de L. C.; COELHO, E. C. F.; FREIRE, R. S.; COUTINHO, F. S.; FERREIRA, J. P. F.; SOUSA, D. B. de; BLANCH, G. T. Benefits of using cannabidiol in the treatment of motor and non-motor symptoms of Parkinson’s disease: A systematic review. Research, Society and Development, [S. l.], v. 14, n. 2, p. e11014248325, 2025. DOI: 10.33448/rsd-v14i2.48325. Disponível em: https://rsdjournal.org/index.php/rsd/article/view/48325. Acesso em: 2 apr. 2025.

Issue

Vol. 14 No. 2

Section

Health Sciences

License

Copyright (c) 2025 Pedro Gabriel de Lima Carneiro Borges; Eduardo Chaves Ferreira Coelho; Ricardo Silva Freire; Fernanda Silva Coutinho; João Paulo Félix Ferreira; Danilo Borges de Sousa; Graziela Torres Blanch

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.